Sildenafil restores endothelial function in the apolipoprotein E knockout mouse

Journal of Translational Medicine

Elisardo C Vasquez¹  Silvana S Meyrelles²  Agata L Gava⁴  Thiago M C Pereira⁶  Isabele B S Gomes³  Marcos A Leal⁵  Camille M Balarini² 

[1] Lab Transgenes and Cardiovascular Control, Dept. of Physiological Sciences, Health Sciences Center, Federal University of Espirito Santo, Av Marechal Campos 1468, 29042-755, Vitoria, ES, Brazil;Dept. of Physiological Sciences, Health Sciences Center, Federal University of Espirito Santo, Vitoria, ES, Brazil;Dept. of Pharmaceutical Sciences, Health Sciences Center, Federal University of Espirito Santo, Vitoria, ES, Brazil;Biotechnology Graduate Program, Health Sciences Center, Federal University of Espirito Santo, Vitoria, ES, Brazil;Emescam College of Health Sciences, Vitoria, ES, Brazil;Department of Pharmaceutical Sciences, University of Vila Velha, Vila Velha, ES, Brazil

关键词: cGMP;    PDE5;    Endothelial dysfunction;    Oxidative stress;    Nitric oxide;    Sildenafil;    ApoE knockout mice;    Atherosclerosis;   

Others  :  1205885
DOI  :  10.1186/1479-5876-11-3

 received in 2012-10-04, accepted in 2013-01-02,  发布年份 2013

【 摘 要 】

Background

Atherosclerosis is an inflammatory process of the arterial walls and is initiated by endothelial dysfunction accompanied by an imbalance in the production of reactive oxygen species (ROS) and nitric oxide (NO). Sildenafil, a selective phosphodiesterase-5 (PDE5) inhibitor used for erectile dysfunction, exerts its cardiovascular effects by enhancing the effects of NO. The aim of this study was to investigate the influence of sildenafil on endothelial function and atherosclerosis progression in apolipoprotein E knockout (apoE^−/−) mice.

Methods

ApoE^−/− mice treated with sildenafil (Viagra®, 40 mg/kg/day, for 3 weeks, by oral gavage) were compared to the untreated apoE^−/− and the wild-type (WT) mice.

Aortic rings were used to evaluate the relaxation responses to acetylcholine (ACh) in all of the groups. In a separate set of experiments, the roles of NO and ROS in the relaxation response to ACh were evaluated by incubating the aortic rings with L-NAME (NO synthase inhibitor) or apocynin (NADPH oxidase inhibitor). In addition, the atherosclerotic lesions were quantified and superoxide production was assessed.

Results

Sildenafil restored the vasodilator response to acetylcholine (ACh) in the aortic rings of the apoE^−/− mice. Treatment with L-NAME abolished the vasodilator responses to ACh in all three groups of mice and revealed an augmented participation of NO in the endothelium-dependent vasodilation in the sildenafil-treated animals. The normalized endothelial function in sildenafil-treated apoE^−/− mice was unaffected by apocynin highlighting the low levels of ROS production in these animals. Moreover, morphological analysis showed that sildenafil treatment caused approximately a 40% decrease in plaque deposition in the aorta.

Conclusion

This is the first study demonstrating the beneficial effects of chronic treatment with sildenafil on endothelial dysfunction and atherosclerosis in a model of spontaneous hypercholesterolemia. These data indicate that the main mechanism of the beneficial effect of sildenafil on the endothelial function appears to involve an enhancement of the NO pathway along with a reduction in oxidative stress.

【 授权许可】

   
2013 Balarini et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
• [2]Libby P, Ridker PM, Hansson GK: Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
• [3]De Meyer GRY, Herman AG: Vascular endothelial dysfunction. Prog Cardiovasc Dis 1997, 39:325-342.
• [4]Meyrelles SS, Peotta VA, Pereira TM, Vasquez EC: Endothelial dysfunction in the apolipoprotein E-deficient mouse: insights into the influence of diet, gender and aging. Lipids Health Dis 2011, 10:211. BioMed Central Full Text
• [5]Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S: Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009, 32:S314-S321.
• [6]Tomasoni L, Sitia S, Borghi C, FG Ca, Ceconi C, Cecaro F, Morganti A, De Gennaro Colonna V, Guazzi M, Morricone L, Malavazos AE, Marino P, Cavallino C, Shoenfeld Y, Turiel M: Effects of treatment strategy on endothelial function. Autoimmun Rev 2010, 9:840-844.
• [7]Palit V, Eardley I: An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction. Nat Rev Urol 2010, 7:603-609.
• [8]Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, Willie G, Ellahham S, Quyyumi AA: The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002, 40:1232-1240.
• [9]Milani E, Nikfar S, Khorasani R, Zamani MJ, Mohammad A: Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Biochem Physiol C Toxicol Pharmacol 2005, 140:251-255.
• [10]Shukla N, Jones R, Persad R, Angelini GD, Jeremy JY: Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolaemic rabbits. Eur J Pharmacol 2005, 517:224-231.
• [11]Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M, Rosano GM: Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. Diabet Med 2008, 25:37-44.
• [12]Plump AS, Smith JD, Hayek T, Aalto-Setälä K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992, 71:343-353.
• [13]Piedrahita JA, Zhang SH, Hagaman JR, Oliver PM, Maeda N: Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992, 89:4471-4475.
• [14]Chiu JJ, Chien S: Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. Physiol Rev 2011, 91:327-387.
• [15]Vasquez EC, Peotta VA, Gava AL, Pereira TMC, Meyrelles SS: Cardiac and vascular phenotypes in the apolipoprotein E-deficient mouse. J Biomed Sci 2012, 19:22. BioMed Central Full Text
• [16]Simonsen U, Rodriguez-Rodriguez R, Dalsgaard T, Buus NH, Stankevicius E: Novel approaches to improving endothelium-dependent nitric oxide-mediated vasodilatation. Pharmacol Rep 2009, 61:105-115.
• [17]Zhang SH, Reddick RL, Burkey B, Maeda N: Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. Journal Clin Invest 1994, 94:937-945.
• [18]Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R: ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994, 14:133-140.
• [19]D’Uscio LV, Barton M, Shaw S, Lüscher TF: Chronic ETA receptor blockade prevents endothelial dysfunction of small arteries in apolipoprotein E-deficient mice. Cardiovasc Res 2002, 53:487-495.
• [20]Jiang F, Gibson AP, Dusting GJ: Endothelial dysfunction induced by oxidized low-density lipoproteins in isolated mouse aorta: a comparison with apolipoprotein-E deficient mice. Eur J Pharmacol 2001, 424:141-149.
• [21]Dussault S, Maingrette F, Ménard C, Michaud S-É, Haddad P, Groleau J, Turgeon J, Perez G, Rivard A: Sildenafil increases endothelial progenitor cell function and improves ischemia-induced neovascularization in hypercholesterolemic apolipoprotein E – deficient mice. Hypertension 2009, 54:1043-1049.
• [22]Zadelaar S, Kleemann R, Verschuren L, De Vries-Vander Weij J, van der Hoorn J, Princen HM, Kooistra T: Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007, 27:1706-1721.
• [23]Zhou Q, Liao JK: Pleiotropic effects of statins. - Basic research and clinical perspectives. Circ J 2010, 74:818-826.
• [24]D’ Uscio LV, Baker TA, Mantilla CB, Smith L, Weiler D, Sieck GC, Katusic ZS: Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2001, 21:1017-1022.
• [25]Kauser K, da Cunha V, Fitch R, Mallari C, Rubanyi GM: Role of endogenous nitric oxide in progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Physiol Heart Circ Physiol 2000, 278:H1679-H1685.
• [26]Koupparis AJ, Jeremy JY, Muzaffar S, Persad R, Shukla N: Sildenafil inhibits the formation of superoxide and the expression of gp47phox NAD[P]H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU Int 2005, 96:423-427.
• [27]Vertuani S, Angusti A, Manfredini S: The antioxidants and pro-antioxidants network: an overview. Curr Pharm Des 2004, 10:1677-1694.
• [28]Rizzo NO, Maloney E, Pham M, Luttrell I, Wessells H, Tateya S, Daum G, Handa P, Schwartz MW, Kim F: Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding. Arterioscler Thromb Vasc Biol 2010, 30:758-765.
• [29]Morihara N, Sumioka I, Ide N, Moriguchi T, Uda N, Kyo E: Aged garlic extract maintains cardiovascular homeostasis in mice and rats. J Nutr 2006, 136:777S-781S.
• [30]Ohashi M, Runge MS, Faraci FM, Heistad DD: MnSOD deficiency increases endothelial dysfunction in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2006, 26:2331-2336.
• [31]Cola MS, Gava AL, Meyrelles SS, Vasquez EC: Endothelial dysfunction of resistance vessels in female apolipoprotein E-deficient mice. Lipids Health Dis 2010, 9:51. BioMed Central Full Text
• [32]Villeneuve N, Fortuno A, Sauvage M, Fournier N, Breugnot C, Jacquemin C, Petit C, Gosgnach W, Carpentier N, Vanhoutte P, Vilaine JP: Persistence of the nitric oxide pathway in the aorta of hypercholesterolemic apolipoprotein-E-deficient mice. J Vasc Res 2003, 40:87-96.
• [33]Arruda RMP, Peotta VA, Meyrelles SS, Vasquez EC: Evaluation of vascular function in apolipoprotein E knockout mice with angiotensin-dependent renovascular hypertension. Hypertension 2005, 46:932-936.
• [34]Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Böhm M, Laufs U: Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008, 117:2377-2387.
• [35]Baumhakel M, Custodis F, Schlimmer N, Laufs U, Böhm M: Improvement of endothelial function of the corpus cavernosum in apolipoprotein E knockout mice treated with irbesartan. J Pharmacol Exp Ther 2008, 327:692-698.
• [36]Chen X, Zhang H, McAfee S, Zhang C: The reciprocal relationship between adiponectin and LOX-1 in the regulation of endothelial dysfunction in ApoE knockout mice. Am J Physiol Heart Circ Physiol 2010, 299:H605-H612.
• [37]Schäfer A, Fraccarollo D, Pförtsch S, Flierl U, Vogt C, Pfrang J, Kobsar A, Renné T, Eigenthaler M, Ertl G, Bauersachs J: Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus. Br J Pharmacol 2008, 153:886-893.
• [38]Bivalacqua TJ, Sussan TE, Gebska MA, Strong TD, Berkowitz DE, Biswal S, Burnett AL, Champion HC: Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction. J Urol 2009, 181:899-906.
• [39]Das A, Xi L, Kukreja RC: Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis, Essential role of nitric oxide signaling. J Biol Chem 2005, 280:12944-12955.
• [40]Salloum F, Yin C, Xi L, Kukreja RC: Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 2003, 92:595-597.
• [41]Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, Qureshi IZ, Hoke NN, Roy SK, Brown WR, Prabhakar S, Kukreja RC: Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 2008, 294:H1398-H1406.
• [42]Matsumoto T, Miyamori K, Kobayashi T, Kamata K: Apocynin normalizes hyperreactivity to phenylephrine in mesenteric arteries from cholesterol-fed mice by improving endothelium-derived hyperpolarizing factor response. Free Radic Biol Med 2006, 41:1289-1303.
• [43]Porto ML, Lima LC, Pereira TM, Nogueira BV, Tonini CL, Campagnaro BP, Meyrelles SS, Vasquez EC: Mononuclear cell therapy attenuates atherosclerosis in apoE KO mice. Lipids Health Dis 2011, 10:155. BioMed Central Full Text
• [44]Lima LCF, Porto ML, Campagnaro BP, Tonini CL, Nogueira BV, Pereira TM, Vasquez EC, Meyrelles SS: Mononuclear cell therapy reverts cuff-induced thrombosis in apolipoprotein E-deficient mice. Lipids Health Dis 2012, 11:96. BioMed Central Full Text
• [45]Moore KJ, Tabas I: Macrophages in the pathogenesis of atherosclerosis. Cell 2011, 145:341-355.